A Decade Study on Transdermal Patches on Cancer Redressal: A Review

A.Santra, S. Shaw, and S. K. Samanta

***Abstract*-- The transdermal patches themselves with different modalities and construction represent an excellent alternative for the different standard procedures of cancer treatment therapy (Breast cancer), pre-evaluation of cancer, and mainly other pain relief treatment which are some most researched domains in medical science. The purpose is to present an overview of the literature of 14 years of research and development for transdermal patches for Cancer and Cancer-related complications. Literature researched in a science-direct database for all types of publication search terms were "Transdermal", "Patches", and "Cancer". The development of transdermal patches is taking place from only pain relief measurements alternative to the pre-clinical evaluation including Cancer therapy alternatives.**

***Index Terms*--Breast Cancer; Estrogen; Fentanyl; Prostate Cancer; Resveratrol; Transdermal Patches**

I. Introduction

Transdermal Patches are medicinal sticky patches positioned on the epidermis to furnish a specific portion of the medicated drug into the epidermis and blood vessels. Transdermal patches are chosen over any other kind of drug delivery system because of their continuous drug delivery, increased biological availability, and decreased drug interaction. Patients with various conditions including hypertension, motion sickness, and pain are reasons behind the construction of transdermal patches. According to WHO, after cardiovascular diseases, the leading cause of demise globally is Cancer with estimated 9.6 million deaths in 2018. Where Lung, Liver, Thyroid, Stomach, and Colorectal cancer are the customary varieties of cancer, while Prostate cancer is in men and Cervical, Breast cancer is in women.

Considering the pain relief management serious associated with treatment research and development had been incorporated into medical science with many trials. From Breast cancer therapy to the development of a microparticle-based transdermal vaccine patch for pre-clinical assessment of metastatic breast cancer and from the transdermal patch (Granisetron patch) CINV treatment of Hematologic cancer patients to the effect of fentanyl patches in cachectic cancer through transdermal, we are drawing the development of transdermal patches over 14years from till date(2008-2022).

II. Transdermal Fentanyl Patch over Opioid Treatment in Cancer

Transdermal fentanyl patches are very widely used in Cancer pain treatment. Unlike Morphine, Fentanyl is about a hundred times more potent, and inaccuracy in dosing may cause conditions from extreme weariness, vomiting, uncertainty, costiveness dyschezia, breathing disorder, and asystole, senselessness to coma and in the worst condition even death along with other negative effects.

To overcome this overdosing complication a 3-day duration fentanyl grid patch has been sketched which has a quarter to half fentanyl content reduction as compared to other patches of fentanyl using the grid tech[1]. The trial is conducted to probe the effectiveness and protectiveness of the newly developed transdermal fentanyl patch.

The effectiveness variable uses a Pain Intensity (PI) scale from 0 to 10, which was monitored every evening (once) for every patient. Here the standard or reference for the experiment was standard opioid treatment. Among 220 randomized patients, 117 were provided FIT patches while 103 were to standard opioid treatment. FIT i.e., Far Infrared Technology(4-21 microns) patches makes use of the emitted infrared radiation which is normally released by body heat. The FIT patches reflect 'far infrared radiation back to the body resulting in a hike in blood circulation beneath the epidermal area of application. After getting all data related to dosing, CI difference, the respective area under the slope, and other influential factors the researcher summarize that the developed grid technology with less medicine dose used in the FIT patch is non-inferior and is just safe as the norm anodyne[1].

III. Transdermal Fentanyl Patches in Cachectic Cancer

Cachexia is estimated to be observed in almost 80% of people with classified cancer. Systemic inflammation, energy balance, negative protein, and loss of body mass(involuntarily) are characterized by cancer cachexia. This Machiavellian syndrome doesn't only impact the quality of patient life but is associated with the chance of decreased survival of the patient and poor retorts to chemotherapy. Malignant and non-malignant cancer chronic pain treatment widely treated by transdermal fentanyl patches the chemical and biological

This work was supported in part by the NSEC, Department of Biomedical Engineering.

Aditya Santra A. Author is with the Department of Biomedical Engineering, Netaji Subhash Engineering College, Garia, WB700152India (e-mail: adityasantra03@gmail.com).

Shuvangi Shaw B. Author, Jr., is with Department of Biomedical Engineering, Netaji Subhash Engineering College, Garia, WB 700152 India (e-mail: shawshuvangi03@gmail.com).

Sujan Krishna Samanta C. Author is with the Biomedical Engineering Department, Netaji Subhash Engineering College, Garia, WB 700152 India (e-mail: itssujan@rediffmail.com)

Volume 2, Issue 2
https:// doi.org/10.15864/ajac.22003

properties of fentanyl suggest high lipid solubility, spinal, and transdermal administration and it is also suitable for the intravenous mode of drug delivery[2]. As cancer cachexia is a condition with many-factor related to etiology: a biological procedure that leads the patient to helplessness to eat, anorexia with hypercatabolism[3], and tissue wasting including enduring inflammation. Those certainly affect the soaking up of fentanyl as the epidermis permeability of cachectic skin gets affected. Xerosis, mostly occurring cutaneous appearances in cachectic patients with malnutrition[4], could be a very significant aspect that is manipulating transdermal medication absorption in the case of patients with cancer[2]. In general, the captivation of fentanyl from the patch is administrated by the superficial zone of the patch, and also by the local bloodstream and the permeability of the skin[5]. The research aims to discover if there is any fentanyl absorption difference in cancer-related pain in cachectic and normal-weighted cancer patients. For this trial, ten cachectic patients and ten normal-weight cancer are enlisted. For 3 days a transdermal fentanyl patch is managed to the very upper arm of the concerned recruited patients containing approximately equal analgesic to the patients previously given opioid doses. Before the doses are incorporated the weight, height, BMI with the thickness of the skin (skin-fold), sweating, and skin temperature are measured along with local blood steam. After the plasma fentanyl concentration is measured at different times such as baseline (at 0th hour), at 4, 24, 48 , and 72 hours interval. In comparison with normal-weight patients, the concentration of plasma fentanyl is significantly lower at 48 hours and 72 hours. Different collected significant data regarding the study like plasma fentanyl concentration ug/L/dose, oxycodone[6], and pain intensity VAS 0-100mm are noted timely. And after analyzing all the data researchers deduced. The clinical inference of transdermal fentanyl infers to not an anodyne of possibility for cachectic cancer patients. Despite the large dose of opioids, low transdermal soaking up of fentanyl was observed in these patients resulting in insufficient analgesia. Additional analysis is needed to survey the components that result in impaired epidermal porosity as well as low fentanyl soaking up in cachectic patients of cancer. Although Pain Intensity showed patients were almost the same in both sections at the base and the climax of the survey. Finally, the survey summed up that transdermal fentanyl absorption is diminished in cachectic patients as compared to that in normal-weighted patients with cancer ailments[2].

IV. Effectiveness of Transdermal Granisetron Patches in Hematological Cancer

Estimation, 1.24 million hematology malignancies occur yearly globally accounting for nearly 6% of cancer cases. The 3 main types of hematologic malignancies: are leukemia, lymphoma, and multiple myeloma chemotherapy regions which are frequently used in the administration of hematologic malignancies and are highly emetogenic. Although there is development in prevention, CINV (Chemotherapy Induced Nausea and Vomiting) can create a considerable barrier to acquiring planned chemotherapy quantity during the delayed phase[7].

The researcher studied the effectiveness of the GTS(Granisetron Transdermal System) against standard oral Granisetron which has been used in managing CINV across several tumor variations. The procedure was similar to published randomized research of the third phase comparing GTS (a week of usage) to oral tradition administering Granisetron (2 mg/day) in patients undergoing either slightly or extremely laxative chemotherapy for 3-5 days. The degree of full control with minimal nausea and complete response with either GTS or deliberately oral Granisetron was compared throughout the immediate (first day) and delayed (days 2 to 5) phases following chemotherapy. The desire for pharmaceutical assistance and the follow-up of response to therapy with GTS were also contrasted. 83 individuals with hematologic cancer were included in the study. The majority of patients were given a non-cisplatin regimen in addition to corticosteroids. The total drug consumption and patient rating of the overall response to treatment were not different across groups. GTS was well-permitted[7].

The researcher also found that the retrospective analysis reveals GTS may be a viable option for CINV prevention in hematologic patients with cancer. In the delayed stages, an enhanced control was noticed and further analysis of the benefit of delayed CINV may be assured[7].

V. tE2 Patches in Prostate Cancer

Cancer in the Prostate gland is a majorly frequent malevolence in men with 3.8% of all deaths caused by cancer. Suppression in Androgen is a medial component to minimize cancer in the prostate gland but causes an everlasting cardio-noxious[8]. Currently, the widely used method is Luteinising Hormone Releasing Hormone Antagonists (LHRHa) to achieve androgen suppression. But LHRHa causes toxicities like loss of muscle mass and impotency resulting in testosterone suppression and many others[9]–[11].

Transdermal oestradiol patches (tE2) were administered which circumvent cardiovascular toxicity as well as estrogen-depleting effects. A randomized trial program, Prostate Adenocarcinoma Transcutaneous Hormone(PATCH) was conducted where patients with a history of most cardio-vascular, thrombophilic, or angina disorders were excluded. The rest were randomly allocated in a computed manner with LHRHa and tE2 patches.

After observation at several intervals, no confirmation of an elevated rate of cardiovascular toxicities was observed in tE2-administered patients. Also, the data collected from PATCH confirmed that the administration of an estradiol transdermal patch abrogated the risk of thrombo-embolic cardiovascular complications rather than orally administered LHRHa[8]. Also in due course of time PATCH is repurposing projects with tE2 patches for Menopausal relief indication in women with a twice-in-a-week application[12].

VI. Resveratrol transdermal patches for breast cancer

In women, the major cause of cancer-related deaths is due to breast cancer[13]. Resveratrol {RVT}, a poly-phenolic

Phyto-estrogen, has revealed anti-proliferative effects in many tumor cells[14]. Traditionally RVT was delivered orally to patients but the assemblage of the drug reaching the active site (breast tissues) was limited. To overcome the issue considering the molecular weight of RVT (228.247 g/mol) makes it suitable for transdermal drug delivery[15].

A research study was conducted to obtain the effectiveness of an enhanced RVT patch in a model mouse, where treatment with 7,12-Dimethylbenz(a)anthracene (DMBA) was persuaded chemically into a batch of rat models where one group had orally administered RVT and the rest had RVT patch[16].

At regular intervals, patches were examined and a considerable change with a brownish-red color was observed[17]. On assessing the QSPR (Quantitative Structure-Property Relationship) tool[18], the partitioning of the penetration enhancers showcased a resemblance among the theoretically predicted and observed flux and aided in decreasing the number of experimental runs (time-preventing). Resulting in a reduction of tumor volume on the treatment of RVT patch as compared to orally administered RVT, giving a positive outcome. However, a circumstantial comprehension of the distribution of breast tissues in women is crucial for drawing any clinical inference. Although to acquire a confined delivery of drugs this method can buy plausibly used[14].

VII. MICROPARTICLE-BASED TRANSDERMAL PATCH IN BREAST CANCER

Among females, breast cancer is the main cause of death due to cancer globally[19]. In the year 2022, roughly 287,850 occurrences of female breast cancer were reported. The survival rate is more than 95 % in breast cancer but is considerably lower when it metastasizes to other organs in the body[20], [21]. Currently, no FDA-approved vaccines for breast cancer are present, thus the demand for a therapeutic breast cancer vaccine that can cure cancer and improve the quality of life[22]. Many vaccine tactics for different cancers are under trial, including breast cancer[23], [24]. Gene transfer-based vaccines require live cultured cells, which is time taking and leads to volatility in inpatient treatment [25]. Furthermore, the devastating growth of breast cancer cells in-vitro state further restricts the availability of patients for clinical trials of vaccine therapy[26]. A recently inferred trial affirmed that one of the main hurdles with gene-based cancer vaccines is the prolonged time in the generation of vaccines that restricts their accessibility to patients[27], [28]. Due to the retard in treatment, the tumor metastasis becomes considerably high, leading to a growth in the tumor and aggravating prophecy[29]. To address these issues, there is a desire for a cancer vaccine that can be promptly made, easily administered, and customized to offer treatment to cancer patients. Usage of biodegradable polymers encapsulating antigens in the grid to prepare the microparticle-based vaccine[30], [31]. To prepare them, the spray drying process is often utilized. After analyzing all of the data from the mouse study, the researcher determined that immunotherapy had the ability to reactivate the rats' impaired immune systems against cancer cells. The results effectively proved the efficiency of epidermal immunization utilizing vaccine microparticles given by microneedles in reducing tumor volume. The survey proposes an alternate method of using the patient's cancer cells to give Tumor-Associated Antigens (TAAs) for the creation of a personalized cancer vaccine. The use of an immune-therapeutic approach offers the potential to improve personalized therapy for difficult-to-treat malignancies. Also, it helps in focusing metastatic cancer-affected cells[32].

VIII. CONCLUSION

After observing different research and review papers of researchers from all over the decade and studying each of the objectives and outcomes of each immune-therapeutic remedy to cancer ailments it can be concluded that even though transdermal patches are flawed for every medication but they have proven fortunate for small-molecule medications. Although, science has significantly enhanced the transdermal drug delivery system for patients with strong responsiveness to oral medications or injections to completely acquire its potential as a substitute for oral delivery and hypodermic injections.

In the future aspect, 1st gen patches probably will continue to be common for the transport of micro-molecule drugs with convenient properties, specifically drugs that are conducted orally and by injection that is coming off patent currently.2nd gen enhancers of chemicals should find frequent use as formulation filling compounds in skin creams and lotions while some patches of systemic manner for small molecule drugs. They might not show much impact on the transport of hydrophilic drugs and macromolecules, because the efficient chemical enhancers generally spread out of the epidermis and irritate deeper tissue. Targeted, 3rd gen blend of enhancers and bio-chemical proceeds to offer tactics for more restricted enhancement, but are in primitive stages of development[33].

IX. REFERENCES

[1] H. G. Kress *et al.*, “A Randomized, Open, Parallel Group, Multicenter Trial to Investigate Analgesic Efficacy and Safety of a New Transdermal Fentanyl Patch Compared to Standard Opioid Treatment in Cancer Pain,” *J Pain Symptom Manage*, vol. 36, no. 3, pp. 268–279, Sep. 2008, doi: 10.1016/j.jpainsymman.2007.10.023.

[2] T. Heiskanen, S. Mätzke, S. Haakana, M. Gergov, E. Vuori, and E. Kalso, “Transdermal fentanyl in cachectic cancer patients,” *Pain*, vol. 144, no. 1–2, pp. 218–222, Jul. 2009, doi: 10.1016/j.pain.2009.04.012.

[3] V. E. Baracos, “Cancer-associated cachexia and underlying biological mechanisms.,” *Annual review of nutrition*, vol. 26. pp. 435–461, 2006. doi: 10.1146/annurev.nutr.26.061505.111151.

[4] C. Hediger, B. Rost, and P. Itin, “Cutaneous manifestations in anorexia nervosa.,” *Schweiz Med Wochenschr*, vol. 130, no. 16, pp. 565–75, Apr. 2000, doi: 10.4414/smw.2000.10064.

[5] S. Grond, L. Radbruch, and K. A. Lehmann, “Clinical Pharmacokinetics of Transdermal Opioids Focus on Transdermal Fentanyl.”

[6] T. Heiskanen and E. Kalso, “Controlled-release oxycodone and morphine in cancer related pain,” 1997.

[7] R. Niesvizky, A. Fernández Velasco, D. S. Wong, and D. Braccia, “Efficacy of a Transdermal Granisetron Patch in Controlling Chemotherapy-Induced Nausea and Vomiting (CINV) in Hematologic Cancer Patients,” *Blood*, vol. 124, no. 21, pp. 3045–3045, Dec. 2014, doi: 10.1182/blood.v124.21.3045.3045.

[8] R. E. Langley *et al.*, “Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme,” 2021. [Online]. Available: www.thelancet.com

[9] S. M. H. Alibhai *et al.*, “Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer,” *Journal of Clinical Oncology*, vol. 28, no. 34, pp. 5038–5045, Dec. 2010, doi: 10.1200/JCO.2010.29.8091.

[10] C. Benedict *et al.*, “Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy,” *Journal of Sexual Medicine*, vol. 11, no. 10, pp. 2571–2580, Oct. 2014, doi: 10.1111/jsm.12645.

[11] L. Bourke, P. Kirkbride, R. Hooper, A. J. Rosario, T. J. A. Chico, and D. J. Rosario, “Endocrine therapy in prostate cancer: Time for reappraisal of risks, benefits and cost-effectiveness?,” *British Journal of Cancer*, vol. 108, no. 1. pp. 9–13, Jan. 15, 2013. doi: 10.1038/bjc.2012.523.

[12] B. W. Walsh, H. Li, and F. M. Sacks, “Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism,” *J Lipid Res*, vol. 35, no. 11, pp. 2083–2093, 1994, doi: 10.1016/s0022-2275(20)39954-5.

[13] B. M. Turner and D. G. Hicks, “Breast cancer,” in *Family Medicine: Principles and Practice*, Springer International Publishing, 2016, pp. 1425–1434. doi: 10.1007/978-3-319-04414-9_114.

[14] S. Gadag*et al.*, “Transpapillary iontophoretic delivery of resveratrol loaded transfersomes for localized delivery to breast cancer,” *Biomaterials Advances*, vol. 140, p. 213085, Sep. 2022, doi: 10.1016/j.bioadv.2022.213085.

[15] O. Lee, D. Ivancic, R. T. Chatterton, A. W. Rademaker, and S. A. Khan, “In vitro human skin permeation of endoxifen: Potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast,” *Breast Cancer: Targets and Therapy*, vol. 3, pp. 61–70, Jul. 2011, doi: 10.2147/BCTT.S20821.

[16] S. Gadag, R. Narayan, Y. Nayak, S. Garg, and U. Y. Nayak, “Design, development and evaluation of Resveratrol transdermal patches for breast cancer therapy,” *Int J Pharm*, vol. 632, p. 122558, Feb. 2023, doi: 10.1016/j.ijpharm.2022.122558.

[17] S. Banerjee, P. Chattopadhyay, A. Ghosh, S. S. Bhattacharya, A. Kundu, and V. Veer, “Accelerated stability testing of a transdermal patch composed of eserine and pralidoxime chloride for prophylaxis against (±)-anatoxin a poisoning,” *J Food Drug Anal*, vol. 22, no. 2, pp. 264–270, Jun. 2014, doi: 10.1016/j.jfda.2014.01.022.

[18] L. H. Hall and L. B. Kier, “Electrotopological State Indices for Atom Types: A Novel Combination of Electronic, Topological, and Valence State Information,” 1995.

[19] H. Sung *et al.*, “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” *CA Cancer J Clin*, vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.

[20] J. Duan *et al.*, “Targeted core-shell nanoparticles for precise CTCF gene insert in treatment of metastatic breast cancer,” *Bioact Mater*, vol. 11, pp. 1–14, May 2022, doi: 10.1016/j.bioactmat.2021.10.007.

[21] G. Jagannathan, M. J. White, R. R. Xian, L. A. Emens, and A. Cimino-Mathews, “A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer,” *Surg Pathol Clin*, vol. 15, no. 1, pp. 105–120, Mar. 2022, doi: 10.1016/j.path.2021.11.007.

[22] M. E. Gatti-Mays, J. M. Redman, J. M. Collins, and M. Bilusic, “Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations,” *Hum VaccinImmunother*, vol. 13, no. 11, pp. 2561–2574, Nov. 2017, doi: 10.1080/21645515.2017.1364322.

[23] R. Benedetti, C. Dell’Aversana, C. Giorgio, R. Astorri, and L. Altucci, “Breast Cancer Vaccines: New Insights,” *Front Endocrinol (Lausanne)*, vol. 8, Oct. 2017, doi: 10.3389/fendo.2017.00270.

[24] E. A. Mittendorf, G. Alatrash, H. Xiao, G. T. Clifton, J. L. Murray, and G. E. Peoples, “Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials,” *Expert Rev Vaccines*, vol. 10, no. 6, pp. 755–774, Jun. 2011, doi: 10.1586/erv.11.59.

[25] M. H. Amer, “Gene therapy for cancer: present status and future perspective,” *Mol Cell Ther*, vol. 2, no. 1, p. 27, 2014, doi: 10.1186/2052-8426-2-27.

[26] X. Dai, H. Cheng, Z. Bai, and J. Li, “Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping,” *J Cancer*, vol. 8, no. 16, pp. 3131–3141, 2017, doi: 10.7150/jca.18457.

[27] L. W. Engel and N. A. Young, “Human breast carcinoma cells in continuous culture: a review.,” *Cancer Res*, vol. 38, no. 11 Pt 2, pp. 4327–39, Nov. 1978.

[28] J. Nemunaitis*et al.*, “Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer,” *JNCI Journal of the National Cancer Institute*, vol. 96, no. 4, pp. 326–331, Feb. 2004, doi: 10.1093/jnci/djh028.

[29] M. Sambi, L. Bagheri, and M. R. Szewczuk, “Current Challenges in Cancer Immunotherapy: Multimodal

Approaches to Improve Efficacy and Patient Response Rates," *J Oncol*, vol. 2019, pp. 1–12, Feb. 2019, doi: 10.1155/2019/4508794.

[30] A. Akalkotkar, S. A. Tawde, L. Chablani, and M. J. D'Souza, "Oral delivery of particulate prostate cancer vaccine: *In vitro* and *in vivo* evaluation," *J Drug Target*, vol. 20, no. 4, pp. 338–346, May 2012, doi: 10.3109/1061186X.2011.654122.

[31] R. P. Gala, M. D'Souza, and S. M. Zughaier, "Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine," *Vaccine*, vol. 34, no. 28, pp. 3260–3267, Jun. 2016, doi: 10.1016/j.vaccine.2016.05.010.

[32] R. U. Zaman, R. P. Gala, A. Bansal, P. Bagwe, and M. J. D'Souza, "Preclinical evaluation of a microparticle-based transdermal vaccine patch against metastatic breast cancer," *Int J Pharm*, vol. 627, p. 122249, Nov. 2022, doi: 10.1016/j.ijpharm.2022.122249.

[33] M. R. Prausnitz and R. Langer, "Transdermal drug delivery," *Nat Biotechnol*, vol. 26, no. 11, pp. 1261–1268, Nov. 2008, doi: 10.1038/nbt.1504.

X. BIOGRAPHIES

Aditya Santra was born on September 12, 2002, in Kolkata, West Bengal, India. He pursued his 12th standard education with pure science group at Jodhpur Park Boys School, Kolkata, West Bengal, India, where he achieved excellent marks. He gained admission to the college through the West Bengal Joint Entrance Examination, Subsequently, He joined Netaji Subhash Engineering College, Garia, West Bengal, India, where he is currently a student in the field of Biomedical Engineering. His major field of study is biomedical engineering, and he has a keen interest in various health tech industries, including pharmacy, biomechanics, nanotechnology, and bio-signal processing.

Shuvangi Shaw was born on January 15, 2002, in Kolkata, West Bengal, India. She excelled in her academic journey, achieving excellent marks in both 10th and 12th standard at Our Lady Queen of the Missions School (QMS), Saltlake, West Bengal, India, where she pursued the science group. Shuvangi's passion for the intersection of technology and healthcare led her to join the Biomedical Engineering program at Netaji Subhash Engineering College, Garia, West Bengal, India, secured through the West Bengal JEE entrance exam. Currently, she is actively pursuing her degree and has shown keen interest in various health tech industries, including pharmacy, instrumentation, nanotechnology, tissue engineering, bio-signal and image processing and biochemistry.

Dr. Sujan Krishna Samanta, born on December 14, 1975, in Tarakeshwar, a city in West Bengal, India, has been a prominent figure in the field of Biomedical Engineering. He completed his education at Jadavpur University in Kolkata, where he earned a degree in Biomedical Engineering.

Currently, Dr. Samanta serves as an Assistant Professor in the Department of Biomedical Engineering at Netaji Subhash Engineering College, West Bengal, India. His passion for teaching and research has made a significant impact on the development of future engineers and researchers. Throughout his career, he has been actively involved in conducting research and has published numerous papers in national and international journals. His areas of expertise lie in the fields of Biomaterials, Tissue Engineering, and Wound Healing.

Among his notable publications are:

"In Vitro and In Vivo Bone Regeneration Assessment of Titanium-Doped Waste Eggshell-Derived Hydroxyapatite in the Animal Model."

"Metallic Ion Doped Tri-Calcium Phosphate Ceramics: Effect of Dynamic Loading on In Vivo Bone Regeneration."

"Study on the Structure and Properties of Crystalline Pure and Doped β-Tri Calcium Phosphate Ceramics."

Before his current position, he held the role of an Assistant Professor at Siliguri Institute of Technology, Siliguri, West Bengal, gaining valuable experience in academia and research.